Amgen loses another round in its battle to fend off a biosimilar rival
March 30, 2015 at 17:06 PM EDT
For the second time this month, Amgen loses a battle over its effort to block a biosimilar version of its Neupogen drug, a $5.7 billion seller that is used to fend off infections during chemotherapy.
